CellSource manufactures processed cells at the Cell Processing Center (CPC), which has obtained a license for manufacturing specified cell products from the Kanto-Shinetsu Regional Bureau of Health and Welfare of the Ministry of Health, Labour and Welfare under the Act on the Safety of Regenerative Medicine.
(Facility Code: FA3160006)
The CPC maintains the cleanliness level specified for each room (Class7,Preparation Room ; Class6, Cell Processing Room; Class 5, Biological Clean Bench).
*According to ISO 14644-1(Particle size: 0.5 μm)
The facility is equipped with dedicated containers for tissues and cells. In these, cells and tissues are stored in the gas phase above the liquid nitrogen where there is less contamination risk. The level of liquid nitrogen is always monitored and maintained by refilling through the automatic refill system.
Born in Niigata Prefecture in 1952, he graduated from Nagoya University School of Medicine in 1978 and completed graduate studies (specializing in pathology and immunology) at the same university in 1983. He is a physician and holds a Ph.D. in medicine. He studied at Stanford University School of Medicine in the United States from 1986. Based on his research results, he co-founded Systemix Inc., a biotech venture company in Silicon Valley, with his mentors in late 1988. As Director of Research, he conducted research and development in gene therapy and cell transplantation therapy. The company successfully went public in 1991, and became a subsidiary of Novartis in 1995, gaining him experience in international R&D. He has published numerous research papers in international academic journals and holds multiple patents. Since 1999, he has worked independently as a consultant in the biotechnology field, supporting many venture companies and serving as a business advisor to major corporations in both Japan and the US, while aiming to promote the bio-healthcare industry in Japan. After 30 years of living in the US, he is now based in Tokyo. Through his involvement in research and development at CellSource, he feels it is his true calling to directly contribute to the implementation of new therapies using adipose tissue and its stem cells.
